FENC
Fennec Pharmaceuticals Inc.
$10.70
+0.36 (+3.48%)
At close · Jul 2
Market Cap
$371.69M
Shares
34,737,030
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.70
Open$10.35
Day$10.30–10.88
52W$5.65–11.31
Avg vol 30d289K
Short int451K · 1.3% float · 2.0d
Short vol20%
Last earningsMar 31, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+32% above
+
Price vs 50-day avg
+22% above
◦
RSI (14)
66 · neutral
+
MACD trend
positive
+
52-week position
89% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $9 › 200d $8 — 50d above 200d
◦
Institutional flow
2 of 90 funds reported for Jun 30 · net 0 sh shares
−
Insider flow
Net -$222.3K over 90 days · 100% sells
+
Short interest
1.30% of float · ▼ -9.5% MoM · 2.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
90 holders — mid 3-yr range
Fundamentals
Weak
−
Revenue growth
−6% Y/Y
+
Gross margin
45%, expanding
−
EPS growth
−1600% Y/Y
−
Free cash flow
$-13.9M
+
Balance sheet
net cash $17.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+32% above
Bullish
Price vs 50-day avg
+22% above
Bullish
RSI (14)
66 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
89% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Flat
2 of 90 funds reported for Jun 30 · net 0 sh shares
Insider flow
Distributing
Net -$222.3K over 90 days · 100% sells
Short interest
Falling
1.30% of float · ▼ -9.5% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
90 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $6
Now $11 · 89%
52-wk high $11
vs 200-day avg +32%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FENC
this stock
Fennec Pharmaceuticals Inc.
|
$371.69M | +39.0% | -6.1% | — | 1.3% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FENC | +1.4% | +17.1% | +41.2% | -0.5% | +39.0% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | 0.0% | +18.3% | +33.1% | -0.2% | +29.7% |